Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsight
DelveInsight's analysis predicts significant growth in the cystic fibrosis market from 2026 to 2036, driven by the launch of emerging therapies such as Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), and others, and increased global healthcare spending. The introduction of new treatments and rising healthcare investments will expand market opportunities and improve patient outcomes.
LAS VEGAS, Oct. 21, 2026 /PRNewswire/ -- Recently published Cystic Fibrosis Market Insights report includes a comprehensive understanding of current treatment practices, cystic fibrosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Cystic Fibrosis Market Summary
- The total cystic fibrosis treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounted for the largest cystic fibrosis treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- There were around 35K diagnosed prevalent cases of cystic fibrosis in the US in 2025, with this number projected to rise over the forecast period from 2026 to 2036.
- Leading cystic fibrosis companies, such as Spexis, Laurent Pharmaceuticals, Arcturus Therapeutics, 4D Molecular Therapeutics, Krystal Biotech, SpliSense, ReCode Therapeutics, Vertex Pharmaceuticals, and others, are developing new cystic fibrosis treatment drugs that can be available in the cystic fibrosis market in the coming years.
- The promising cystic fibrosis therapies in clinical trials include Lonodelestat, LAU-7b, ARCT-032, 4D-710, KB407, SPL84, SPL23, RCT2100, Ivacaftor, and others.
Discover the future of the cystic fibrosis therapeutics market @ https://www.delveinsight.com/report-store/cystic-fibrosis-market
Key Factors Driving the Growth of the Cystic Fibrosis Market
- Rising Prevalence of Cystic Fibrosis: The growing prevalence and continued identification of cystic fibrosis cases are expanding the overall patient pool requiring long-term treatment and disease management. Improved disease recognition and screening are also contributing to higher case detection across various regions.
- Expanding Adoption of CFTR Modulators: Increasing use of CFTR modulator therapies is a major market driver, particularly as more patients become eligible for genotype-specific treatments. Wider adoption of highly effective modulator combinations is improving clinical outcomes and supporting sustained treatment demand.
- Increasing Focus on Personalized Medicine: Greater understanding of CFTR mutations is enabling treatment strategies tailored to individual genetic profiles. The growing emphasis on precision medicine is supporting the development and adoption of mutation-specific and personalized therapeutic approaches.
- Development of Next-Generation Therapies: Pharmaceutical companies are pursuing novel therapies, including Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), SPL84 and SPL23 (SpliSense), RCT2100 (ReCode Therapeutics), Ivacaftor (Vertex Pharmaceuticals), and others. These innovations could expand treatment options for patients who remain underserved by existing therapies.
Shikha Bhardwaj, Associate Consultant of Forecasting & Analytics at DelveInsight, said, "ALYFTREK demonstrates strong clinical and commercial value, with the potential to deliver improved patient outcomes and convenient once-daily dosing, supported by rapid NHS access and reimbursement agreements that are enhancing adoption."
Cystic Fibrosis Market Analysis
- The cystic fibrosis treatment landscape is undergoing significant transformation, largely driven by the widespread adoption of CFTR modulators, which are now accessible to the majority of eligible patients. This shift is positioning cystic fibrosis increasingly as a chronic, manageable condition.
- However, substantial unmet needs remain among patients who are not eligible for CFTR modulators, while persistent disparities in global treatment access continue to influence innovation and market expansion.
- The cystic fibrosis market is largely dominated by CFTR modulators, with Vertex Pharmaceuticals maintaining a strong leadership position through its portfolio of ALYFTREK, TRIKAFTA, SYMDEKO, and ORKAMBI, which collectively contribute a significant share of global market revenues.
- Market expansion is being supported by broader access and label extensions for CFTR modulators, including their use in younger age groups and patients with a wider range of CFTR mutations.
- The market is anticipated to experience steady growth, supported by sustained uptake of established therapies and the emergence of novel treatments offering improved efficacy, broader patient coverage, and potentially disease-modifying effects.
- The evolving pipeline, which includes candidates such as Lonodelestat, LAU-7b, and ARCT-032, among others, highlights ongoing efforts to address residual unmet needs, expand treatment options, and further improve outcomes for patients with cystic fibrosis.
Cystic Fibrosis Competitive Landscape
Some of the cystic fibrosis drugs under development include Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), SPL84 and SPL23 (SpliSense), RCT2100 (ReCode Therapeutics), Ivacaftor (Vertex Pharmaceuticals), and others.
Spexis' Lonodelestat is an investigational inhaled therapy designed to inhibit neutrophil elastase, an enzyme associated with pulmonary inflammation and tissue damage in patients with cystic fibrosis. By blocking neutrophil elastase activity, Lonodelestat is intended to reduce lung inflammation and potentially preserve or improve pulmonary function. The therapy is currently being evaluated in Phase II clinical trials to assess its safety and efficacy in cystic fibrosis. Findings from these studies will help determine its potential for further development, regulatory approval, and clinical use.
Laurent Pharmaceuticals' LAU-7b (fenretinide) is a novel oral formulation of fenretinide, an atypical retinoid that modulates specific cell membrane lipids involved in viral replication and immune-inflammatory pathways. As the company's lead drug candidate, LAU-7b is a patent-protected oral formulation designed to support a convenient once-daily, low-dose treatment regimen. The candidate has completed Phase II clinical development for cystic fibrosis.
Arcturus Therapeutics' ARCT-032 is an investigational inhaled mRNA therapy delivered using LUNAR, a lipid-mediated delivery platform that encapsulates mRNA within lipid nanoparticles. In February 2024, the European Commission granted Orphan Medicinal Product Designation to ARCT-032 for the treatment of cystic fibrosis following a positive opinion from the European Medicines Agency. The candidate had previously received Rare Pediatric Disease Designation from the FDA in October 2023 and Orphan Drug Designation in November 2023. In October 2025, the company reported interim results from its ongoing Phase II clinical trial evaluating ARCT-032 in patients with cystic fibrosis.
4D Molecular Therapeutics' 4D-710 is an investigational genetic medicine candidate that utilizes the A101 vector to target the underlying cause of cystic fibrosis lung disease. The candidate is being evaluated in a Phase 1/2 clinical study in patients with cystic fibrosis who are ineligible for CFTR modulator therapy or have discontinued treatment because of adverse effects. 4D-710 is designed for single-dose aerosol administration to deliver a corrective CFTRΔR transgene throughout the airways and alveoli. Its mutation-agnostic approach is intended to provide a disease-modifying effect regardless of the patient's specific CFTR mutation.
The anticipated launch of these emerging therapies are poised to transform the cystic fibrosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the cystic fibrosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the cystic fibrosis treatment pipeline @ Cystic Fibrosis Drug Pipeline
Cystic Fibrosis Epidemiology Segmentation
The cystic fibrosis epidemiology section provides insights into the historical and current cystic fibrosis patient pool and forecasted trends for the leading markets. Recent trends in cystic fibrosis indicate that Staphylococcus aureus and Pseudomonas aeruginosa remain the most prevalent pathogens, driving a large share of infections.
The cystic fibrosis treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
- Diagnosed Prevalent Cases of Cystic Fibrosis
- Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis
- Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis
- Mutation-specific Diagnosed Prevalent Cases of Cystic Fibrosis
- Microorganism-specific Diagnosed Prevalent Cases of Cystic Fibrosis
Cystic Fibrosis Market Report Metrics | Details |
Study Period | 2022–2036 |
Coverage | 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. |
Cystic Fibrosis Epidemiology Segmentation | Diagnosed Prevalent Cases of Cystic Fibrosis, Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis, Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis, Mutation-specific Diagnosed Prevalent Cases of Cystic Fibrosis, and Microorganism-specific Diagnosed Prevalent Cases of Cystic Fibrosis |
Key Cystic Fibrosis Companies | Spexis, Laurent Pharmaceuticals, Arcturus Therapeutics, 4D Molecular Therapeutics, Krystal Biotech, SpliSense, ReCode Therapeutics, Vertex Pharmaceuticals, and others |
Key Cystic Fibrosis Therapies | Lonodelestat, LAU-7b, ARCT-032, 4D-710, KB407, SPL84, SPL23, RCT2100, Ivacaftor, ALYFTREK, TRIKAFTA, SYMDEKO, ORKAMBI, and others |
Scope of the Cystic Fibrosis Market Report
- Cystic Fibrosis Patient Population Forecast
- Cystic Fibrosis Therapeutics Market Size
- Cystic Fibrosis Pipeline Analysis
- Cystic Fibrosis Market Size and Trends
- Cystic Fibrosis Market Opportunity
- Cystic Fibrosis Market Unmet Needs
- KOL's Views on Cystic Fibrosis
- Cystic Fibrosis Market Access and Reimbursement
Download the report to understand the cystic fibrosis pipeline @ Cystic Fibrosis Clinical Trials
Table of Contents
1 | Cystic Fibrosis Market Key Insights |
2 | Cystic Fibrosis Market Report Introduction |
3 | Executive Summary |
4 | Key Events |
5 | Epidemiology and Market Forecast Methodology |
6 | Cystic Fibrosis Market Overview at a Glance |
6.1 | Clinical Landscape Analysis (By Mechanism of Action [MoA] and Molecule Type) |
6.2 | Market Share (%) Distribution of Cystic Fibrosis in 2025 |
6.3 | Market Share (%) Distribution of Cystic Fibrosis in 2036 |
7 | Disease Background and Overview |
7.1 | Introduction |
7.2 | Signs and Symptoms |
7.3 | Causes |
7.4 | Related Conditions |
7.5 | Etiology |
7.6 | Risk Factors |
7.7 | Pathophysiology |
7.8 | Complications |
7.9 | Diagnosis |
7.10 | Management and Treatment |
8 | Epidemiology and Patient Population |
8.1 | Key Findings |
8.2 | Assumptions and Rationale: The 7MM |
8.3 | Total Diagnosed Prevalent Cases of Cystic Fibrosis in the 7MM |
8.4 | The US |
8.4.1 | Diagnosed Prevalent Cases of Cystic Fibrosis in the US |
8.4.2 | Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis in the US |
8.4.3 | Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis in the US |
8.4.4 | Mutation-specific Diagnosed Prevalent Cases of Cystic Fibrosis in the US |
8.4.5 | Microorganism-specific Diagnosed Prevalent Cases of Cystic Fibrosis in the US |
8.5 | EU4 and the UK |
8.6 | Japan |
9 | Patient Journey of Cystic Fibrosis |
10 | Marketed Cystic Fibrosis Drugs |
10.1 | Marketed Key Cross |
10.2 | ALYFTREK: Vertex Pharmaceuticals |
10.2.1 | Product Description |
10.2.2 | Regulatory Milestones |
10.2.3 | Other Developmental Activities |
10.2.4 | Clinical Trial Information |
10.2.5 | Safety And Efficacy |
10.3 | TRIKAFTA: Vertex Pharmaceuticals |
10.4 | SYMDEKO: Vertex Pharmaceuticals |
10.5 | ORKAMBI: Vertex Pharmaceuticals |
List to be continued in the report | |
11 | Emerging Cystic Fibrosis Drugs |
11.1 | Key Cross Competition |
11.2 | LAU-7b: Laurent Pharmaceuticals |
11.2.1 | Product Description |
11.2.2 | Other Development Activities |
11.2.3 | Clinical Trial Information |
11.2.4 | Safety And Efficacy |
11.2.5 | Analyst's Views |
11.3 | Lonodelestat: Spexis |
11.4 | ARCT-032: Arcturus Therapeutics |
List to be continued in the report | |
12 | Cystic Fibrosis Market Analysis |
12.1 | Key Findings |
12.2 | Key Cystic Fibrosis Market Forecast Assumptions |
12.3 | Cystic Fibrosis Market Outlook |
12.4 | Conjoint Analysis |
12.5 | Total Market Size of Cystic Fibrosis in the 7MM |
12.6 | Total Market Size of Cystic Fibrosis by Therapies in the 7MM |
12.7 | Market Size of Cystic Fibrosis in the US |
12.7.1 | Total Market Size of Cystic Fibrosis |
12.7.2 | The Market Size of Cystic Fibrosis by Therapies |
12.8 | Market Size of Cystic Fibrosis in EU4 and the UK |
12.9 | Market Size of Cystic Fibrosis in Japan |
13 | KOL Opinion Leaders' Views of Cystic Fibrosis |
14 | SWOT Analysis of Cystic Fibrosis |
15 | Unmet Needs of Cystic Fibrosis |
16 | Market Access and Reimbursement |
16.1 | The US |
16.2 | In EU4 and the UK |
16.3 | Japan |
16.4 | Summary and Comparison of Market Access and Pricing Policy Developments in 2025 |
16.5 | Market Access and Reimbursement of Cystic Fibrosis Therapies |
17 | Bibliography |
18 | Acronyms and Abbreviations |
19 | Cystic Fibrosis Market Report Methodology |
Related Reports
Cystic Fibrosis Clinical Trial Analysis
Cystic Fibrosis Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cystic fibrosis companies, including Eloxx Pharmaceuticals, Arrowhead Pharmaceuticals, SolAeroMed, Parion Sciences, Translate Bio, Inc., Path BioAnalytics, Aridis Pharmaceuticals, Novartis, Vertex Pharmaceuticals, AlgiPharma, Proteostasis Therapeutics, Inc., Galapagos NV, Santhera Pharmaceuticals, Calithera Biosciences, Inc., Spyryx Biosciences, Inc., Verona Pharma, Ionis Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Ligand Pharmaceuticals, Boehringer Ingelheim, OrPro Therapeutics, Protalix Biotherapeutics, Laurent Pharmaceuticals, Arcturus Therapeutics, Enterprise Therapeutics, Affinia Therapeutics, AlgiPharma AS, Sound Pharmaceuticals, Spirovant, 4D Molecular Therapeutics, Santhera Pharmaceuticals, Armata Pharmaceuticals, and others.
Non-Cystic Fibrosis Bronchiectasis Market
Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NCFB companies, including Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others.
Bronchiectasis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bronchiectasis companies, including Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A., CSL, GlaxoSmithKline, Insmed, and others.
DPP1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DPP1 inhibitors companies, including Boehringer Ingelheim, Fosun Pharma, Expedition Therapeutics, Haisco Pharmaceutical Group, Chiesi, Melodia Therapeutics, Alivexis, Insmed, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Share this article